Cancer is one of the
most serious and chronic disorders presently. It is a highly
dangerous disease with a high mortality rate due to extremely
invasive nature and prolonged duration. Metastatic bone disease is
one of the types of cancer which begins in an organ such as breast,
prostate, or lungs and spreads to bone. According to a recent study,
around 1.2 million new cancer patients are diagnosed each year.
Nearly 50% of these tumors can progress to metastatic bone disease.
This growth can be benign or malignant. In most of the cases, bone
cancer is a result of other cancers such as breast, thyroid, lung,
kidney, and prostate.
Request a
Brochure of the Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37802
Due to advance
medical treatment of many cancers especially for breast prostate, or
lungs patients can live longer. The primary and major indication of
metastatic bone disease is intolerable and severe bone pain. The
severity of pain increases with time. In addition to pain, other
symptoms such as fatigue, weight loss, bone crack, muscle pain,
fever, osteopenia, and osteoporosis have been identified. The
diagnostic tests may include reasons of pain and deep study of
patient’s history. Diagnosis of metastatic bone disease is carried
out using imaging tests such as CT scan, PET scanning, MRI, and bone
scanning. Biopsy is another test used for the diagnosis and
confirmation of the disease.
The global
metastatic bone disease market is expected to grow substantially due
to rise in awareness among the population about metastatic bone
disease and other bone diseases, increase in R&D investment by
major players across the globe, technological advancements, and
improvement in medical infrastructure. However, high cost of R&D,
diagnosis, and treatment acts as a major restraint of the market.
Request for the
TOC of the Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=37802
The global
metastatic bone disease market can be segmented based on type of bone
cancer, type of therapy, and region. In terms of type of cancer, the
market can be bifurcated into primary bone cancer and secondary bone
cancer. Primary bone cancer is characterized by rapid and
uncontrollable growth of bone and related tissues. Secondary bone
cancer originates from another site of body and metastasizes to the
bone structure. Based on type of therapy, the global metastatic bone
disease market can be divided into radiation therapy, chemotherapy,
cryosurgery, and surgical treatments. Radiation therapy uses X-rays
or gamma-rays to treat the disease. Chemotherapy uses anti-cancer
drugs either orally 1or parenterally to treat the disease.
Geographically, the
global metastatic bone disease market can be segmented into North
America, Europe, Latin America, Asia Pacific, and Middle East &
Africa. Each region can be sub-divided into specific countries such
as the U.S., Canada, Germany, the U.K., Brazil, China, India, Japan,
and GCC Countries. North America dominates the market owing to
rapidly rising incidence of bone cancers and increasing focus on R&D
in bone tumor treatments. Asia Pacific is projected to be the most
attractive market during the forecast period due to rise in health
care awareness and demand for advanced medical technology.
Enquiry for
discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=37802
Key players
operating in the global metastatic bone disease market are Amgen,
Inc., Novartis International AG, Actavis plc, Pfizer, Inc.,
Debiopharm Group, and Eli Lilly and Company, among others. These
players have adopted various growth strategies such as
collaborations, agreements, partnerships, and new product launches to
gain competitive advantage in the market.
About Us
Transparency Market
Research (TMR) is a market intelligence company, providing global
business information reports and services. Our exclusive blend of
quantitative forecasting and trends analysis provides forward-looking
insight for thousands of decision makers. TMR’s experienced team of
analysts, researchers, and consultants, use proprietary data sources
and various tools and techniques to gather, and analyze information.
Our business offerings represent the latest and the most reliable
information indispensable for businesses to sustain a competitive
edge.
Each TMR syndicated
research report covers a different sector - such as pharmaceuticals,
chemicals, energy, food & beverages, semiconductors, med-devices,
consumer goods and technology. These reports provide in-depth
analysis and deep segmentation to possible micro levels. With wider
scope and stratified research methodology, TMR’s syndicated reports
strive to provide clients to serve their overall research
requirement.
US Office
Contact
90 State Street,
Suite 700
Albany, NY 12207
Tel:
+1-518-618-1030
USA - Canada Toll
Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment